Sugi Predict

Sugi Predict / Compounds / SCHEMBL2284207

SCHEMBL2284207

SCHEMBL2284207

O=C(O)c1ccc2[nH]c(-c3ccccc3)c(-c3ccccc3)c2c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.63
▸ ESR1 P03372 3/20 0.59
▸ ESR2 Q92731 3/20 0.59
▸ FLT3 P36888 1/20 0.56
▸ KDM4E B2RXH2 4/20 0.54
▸ GFER P55789 2/20 0.54
▸ MAPT P10636 1/20 0.54
▸ PIM1 P11309 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.51
▸ HPGD P15428 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ HTT P42858 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ MAP2 P11137 1/20 0.51
▸ PTGS2 P35354 8/20 0.51
▸ THRB P10828 1/20 0.50
▸ F2 P00734 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10990966 0.86 ESR1 (0.71) PPARGESR1ESR2KDM4EGFER
SCHEMBL2285692 0.84 MEN1 (0.71) PPARGESR1ESR2FLT3KDM4E
SCHEMBL6950615 0.83 KDM4E (0.65) PPARGFLT3KDM4EGFERMAPT
SCHEMBL6951106 0.83 F2 (0.70) PPARGFLT3KDM4EGFERMAPT
SCHEMBL11093418 0.80 PPARG (0.61) PPARGFLT3KDM4EGFERALDH1A1
SCHEMBL11556128 0.80 PPARG (0.51) PPARGFLT3KDM4EGFERMAPT
SCHEMBL7037982 0.79 ESR1 (0.77) ESR1ESR2KDM4EGFERMAPT
SCHEMBL7041577 0.79 ESR1 (0.73) ESR1ESR2KDM4EMAPTTDP1
SCHEMBL29823892 0.78 KDM4E (0.60) PPARGFLT3KDM4EMAPTALDH1A1
SCHEMBL18552201 0.78 ESR1 (0.69) ESR1ESR2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207732-A1 AZAINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-08-25 — — US claimed
EP-3030559-B1 URAZOLE COMPOUNDS UNIV GENT (BE) 2017-06-28 — — EP disclosed
US-9586935-B2 Urazole compounds UNIVERSITEIT GENT (BE) 2017-03-07 — — US disclosed
US-9586935-B2 Urazole compounds UNIVERSITEIT GENT (BE) 2017-03-07 — — US disclosed
US-20160200707-A1 URAZOLE COMPOUNDS UNIVERSITEIT GENT (BE) 2016-07-14 — — US disclosed
US-20160200707-A1 URAZOLE COMPOUNDS UNIVERSITEIT GENT (BE) 2016-07-14 — — US disclosed
WO-2015018928-A1 URAZOLE COMPOUNDS UNIVERSITEIT GENT (BE) 2015-02-12 — — WO disclosed
US-20110207732-A1 AZAINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-08-25 — — US disclosed
US-20110207732-A1 AZAINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-08-25 — — US disclosed
WO-2010046013-A1 AZAINDOLE DERIVATIVE MERCK PATENT GMBH (DE) 2010-04-29 — — WO disclosed
EP-1261601-B1 SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-29 — — EP disclosed
US-7342029-B2 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-03-11 — — US disclosed
US-20050282866-A1 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-12-22 — — US disclosed
US-20040209868-A1 Substituted indoles AVENTIS PHARMA DEUTSCHLAND GMBH 2004-10-21 — — US disclosed
US-20030119820-A1 Therapy of disorders resulting from increased activity of nuclear factor kappa-beta AVENTIS PHARMA DEUTSCHLAND GMBH 2003-06-26 — — US disclosed
EP-1261601-A1 SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY Aventis Pharma Deutschland GmbH (DE) 2002-12-04 — — EP disclosed
WO-2001030774-A1 SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209868-A1 Substituted indoles NFKBIA, IKBKG, IKBKB PPARG 2824/4885ESR1 2822/4885ESR2 1522/4885
US-20030119820-A1 Therapy of disorders resulting from increased activity of nuclear factor kappa-beta NFKBIA, NFKB1, NFKB2 PPARG 955/4885ESR1 2450/4885ESR2 454/4885
US-20160200707-A1 URAZOLE COMPOUNDS UFL1, UFM1, SULT1E1 PPARG 4172/4885ESR1 791/4885ESR2 1322/4885
US-20110207732-A1 AZAINDOLE DERIVATIVES AZI2, ABL1, RET PPARG 4204/4885ESR1 959/4885ESR2 1119/4885
US-20050282866-A1 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis NFKBIA, IKBKB, IKBKE PPARG 1750/4885ESR1 3292/4885ESR2 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.